…
Zynex, Inc., together with its subsidiaries, designs, manufactures, and markets medical devices to treat chronic and acute pain, and activate and exercise muscles for rehabilitative purposes with electrical stimulation. The company offers NexWave, a dual channel, multi-modality interferential current, transcutaneous electrical nerve stimulation, and neuromuscular electrical stimulation (NMES) device that is marketed to physicians and therapists by field sales representatives; NeuroMove, an electromyography and electric stimulation technology device; InWave, an electrical stimulation product for the treatment of female urinary incontinence; E-Wave, an NMES device; and M-Wave, an NMES device. It also supplies private labeled products, including electrodes for the delivery of electrical current to the body; and batteries for use in electrotherapy products. In addition, the company distributes Comfortrac/Saunders for cervical traction, JetStream for hot/cold therapy, LSO Back Braces for lumbar support, braces for rehabilitation support for knee and wrist, and Dynacomp for cold compression therapy. Further, it develops Zynex Fluid Monitoring System (CM-1500); Zynex Wireless Fluid Monitoring System (CM-1600), a noninvasive monitoring device designed to measure relative changes in fluid volume in adult patients; NiCO CO-Oximeter, a laser photoplethysmographic patient monitoring device; and HemeOx tHb Oximeter, a laser-based total hemoglobin pulse oximeter. The company provides its products for use in pain management and control; stroke and spinal cord injury rehabilitation; and fluid monitoring and pulse oximetry monitoring. It sells its products through direct sales force primarily in the United States. Zynex, Inc. was founded in 1996 and is headquartered in Englewood, Colorado.
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.
| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Income before tax | 22.20M | 22.27M | 10.15M | 11.94M | 10.22M |
| Minority interest | - | - | - | -0.09M | -0.09M |
| Net income | 17.05M | 17.10M | 9.07M | 9.49M | 9.55M |
| Selling general administrative | 36.11M | 26.32M | 18.32M | 11.58M | 15.51M |
| Selling and marketing expenses | 67.12M | 54.29M | 34.13M | 14.02M | - |
| Gross profit | 126.16M | 102.98M | 62.70M | 36.66M | 25.88M |
| Reconciled depreciation | 3.13M | 2.29M | 1.57M | 0.78M | 0.45M |
| Ebit | 19.81M | 20.08M | 10.25M | 10.29M | 9.92M |
| Ebitda | 22.94M | 22.37M | 11.74M | 11.07M | 10.37M |
| Depreciation and amortization | 3.13M | 2.29M | 1.50M | 0.78M | 0.45M |
| Non operating income net other | -0.30M | - | -0.08M | 0.88M | - |
| Operating income | 22.94M | 22.37M | 10.25M | 11.07M | 10.37M |
| Other operating expenses | 135.23M | 107.94M | 69.87M | 34.41M | 21.55M |
| Interest expense | 0.44M | 0.10M | 0.02M | 0.01M | 0.15M |
| Tax provision | 5.15M | 5.17M | 1.08M | 2.45M | 0.66M |
| Interest income | - | - | - | 0.01M | 0.15M |
| Net interest income | -0.44M | -0.10M | -0.02M | -0.01M | -0.15M |
| Income tax expense | 5.15M | 5.17M | 1.08M | 2.45M | 0.66M |
| Total revenue | 158.17M | 130.30M | 80.12M | 45.47M | 31.92M |
| Total operating expenses | 103.22M | 80.61M | 52.46M | 25.59M | 15.51M |
| Cost of revenue | 32.01M | 27.32M | 17.42M | 8.81M | 6.04M |
| Total other income expense net | -0.74M | -0.10M | -0.10M | 0.88M | -0.15M |
| Net income from continuing ops | 17.05M | 17.10M | 9.07M | 9.49M | 9.55M |
| Net income applicable to common shares | 17.05M | 17.10M | 9.07M | 9.49M | 9.55M |
| Breakdown | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 |
| Total assets | 122.08M | 141.07M | 116.47M | 133.27M | 72.17M |
| Intangible assets | 7.25M | 8.16M | 9.07M | 9.97M | - |
| Other current assets | 3.61M | 3.33M | 0.87M | 0.69M | 1.38M |
| Total liab | 86.37M | 94.94M | 50.11M | 59.35M | 15.32M |
| Total stockholder equity | 35.71M | 46.13M | 66.36M | 73.92M | 56.85M |
| Other current liab | 9.77M | 5.54M | 5.99M | 9.82M | 3.27M |
| Common stock | 0.03M | 0.03M | 0.04M | 0.04M | 0.04M |
| Capital stock | 0.03M | 0.03M | 0.04M | 0.04M | 0.04M |
| Retained earnings | 29.77M | 26.78M | 17.05M | 0.00M | 23.43M |
| Other liab | - | - | 10.00M | 9.70M | - |
| Good will | 20.40M | 20.40M | 20.40M | 20.40M | - |
| Other assets | - | 0.00M | 2.15M | 1.30M | 0.91M |
| Cash | 39.63M | 44.58M | 20.14M | 42.61M | 39.17M |
| Total current liabilities | 16.86M | 18.53M | 21.09M | 22.87M | 10.12M |
| Current deferred revenue | - | 0.63M | 1.56M | - | - |
| Net debt | 34.19M | 31.59M | 6.82M | -7.52M | -31.84M |
| Short term debt | 4.32M | 3.92M | 7.94M | 8.31M | 2.13M |
| Short long term debt | - | - | 5.33M | 5.33M | - |
| Short long term debt total | 73.82M | 76.17M | 26.96M | 35.09M | 7.33M |
| Other stockholder equity | 5.90M | 19.32M | 49.27M | 73.88M | 33.39M |
| Property plant equipment | - | - | 2.17M | 18.91M | 1.93M |
| Total current assets | 75.18M | 87.86M | 69.56M | 82.69M | 63.02M |
| Net tangible assets | - | - | 36.89M | 43.55M | 56.85M |
| Net receivables | 18.02M | 26.84M | 35.06M | 28.63M | 13.84M |
| Long term debt | 58.57M | 57.60M | 5.29M | 10.61M | - |
| Inventory | 13.92M | 13.11M | 13.48M | 10.76M | 8.63M |
| Accounts payable | 7.09M | 8.43M | 5.60M | 4.74M | 4.72M |
| Accumulated other comprehensive income | - | 0.00M | - | - | - |
| Common stock total equity | - | - | 0.04M | 0.04M | 0.04M |
| Retained earnings total equity | - | - | 17.05M | - | 23.43M |
| Treasury stock | - | - | - | -6.51M | -3.85M |
| Non currrent assets other | 1.55M | -7.75M | 0.86M | 0.97M | 0.67M |
| Non current assets total | 46.90M | 53.22M | 46.91M | 50.59M | 9.15M |
| Capital lease obligations | 15.26M | 18.56M | 16.33M | 19.15M | 7.33M |
| Long term debt total | - | - | 5.29M | 10.61M | - |
| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Investments | -0.42M | -16.61M | -0.98M | -0.16M | -1.08M |
| Change to liabilities | 1.83M | 2.89M | 3.77M | 0.79M | 0.35M |
| Total cashflows from investing activities | -0.42M | -16.61M | -0.98M | -0.16M | -1.08M |
| Net borrowings | -5.33M | 15.95M | -0.06M | -0.02M | -0.51M |
| Total cash from financing activities | -35.80M | 13.10M | 25.30M | -2.23M | -3.76M |
| Change to operating activities | -0.19M | 0.45M | -0.67M | 0.31M | 0.06M |
| Net income | 17.05M | 17.10M | 9.07M | 9.49M | 9.55M |
| Change in cash | -22.47M | 3.44M | 25.13M | 3.91M | 4.56M |
| Begin period cash flow | 42.61M | 39.17M | 14.04M | 10.13M | 5.57M |
| End period cash flow | 20.14M | 42.61M | 39.17M | 14.04M | 10.13M |
| Total cash from operating activities | 13.75M | 6.95M | 0.82M | 6.30M | 9.41M |
| Issuance of capital stock | - | 0.00M | 25.20M | 0.22M | 0.18M |
| Depreciation | 3.13M | 2.29M | 1.57M | 0.78M | 0.45M |
| Other cashflows from investing activities | - | -16.00M | - | - | - |
| Dividends paid | 3.61M | 0.00M | 0.00M | 2.26M | 2.27M |
| Change to inventory | -4.32M | -3.78M | -7.32M | -2.36M | -0.41M |
| Change to account receivables | -6.43M | -14.78M | -8.00M | -3.04M | -0.61M |
| Sale purchase of stock | -26.43M | -2.67M | 25.77M | -0.17M | -3.43M |
| Other cashflows from financing activities | -0.35M | -0.25M | 0.15M | -0.16M | -1.08M |
| Change to netincome | 1.79M | 1.48M | 2.63M | 1.22M | -0.35M |
| Capital expenditures | 0.42M | 0.61M | 0.98M | 0.16M | 1.08M |
| Change receivables | -6.43M | -14.78M | -8.00M | -3.04M | -0.61M |
| Cash flows other operating | 0.70M | 1.74M | -0.90M | -0.57M | 0.27M |
| Cash and cash equivalents changes | -22.47M | 3.44M | 25.13M | 3.91M | 4.56M |
| Change in working capital | -9.10M | -15.21M | -12.22M | -4.30M | -0.61M |
| Stock based compensation | 2.34M | 1.63M | 2.68M | 0.82M | 0.37M |
| Other non cash items | 1.18M | 1.29M | -0.24M | -0.69M | 0.37M |
| Free cash flow | 13.33M | 6.34M | -0.17M | 6.14M | 8.33M |
Sector: Healthcare Industry: Medical Distribution
|
Stock Name
|
Change
(USD) |
Price
(USD) |
Trailing
PE (x) |
Forward
PE (x) |
Price Sales
TTM (x) |
Price to Book Value (x)
|
Enterprise Value
to Revenue (x) |
Enterprise Value
to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| MCK McKesson Corporation |
2.41 0.22% |
1082.20 | 24.45 | 20.41 | 0.26 | 5.04 | 0.27 | 15.03 |
| COR Cencora Inc. |
1.29 0.37% |
351.17 | 24.22 | 16.39 | 0.19 | 20.41 | 0.21 | 13.72 |
| CAH Cardinal Health Inc |
2.00 0.72% |
279.45 | 29.48 | 17.92 | 0.20 | 16.07 | 0.22 | 15.67 |
| HSIC Henry Schein Inc |
-0.06 0.07% |
88.36 | 25.89 | 15.08 | 0.72 | 3.14 | 1.00 | 13.43 |
Zynex, Inc., together with its subsidiaries, designs, manufactures, and markets medical devices to treat chronic and acute pain, and activate and exercise muscles for rehabilitative purposes with electrical stimulation. The company offers NexWave, a dual channel, multi-modality interferential current, transcutaneous electrical nerve stimulation, and neuromuscular electrical stimulation (NMES) device that is marketed to physicians and therapists by field sales representatives; NeuroMove, an electromyography and electric stimulation technology device; InWave, an electrical stimulation product for the treatment of female urinary incontinence; E-Wave, an NMES device; and M-Wave, an NMES device. It also supplies private labeled products, including electrodes for the delivery of electrical current to the body; and batteries for use in electrotherapy products. In addition, the company distributes Comfortrac/Saunders for cervical traction, JetStream for hot/cold therapy, LSO Back Braces for lumbar support, braces for rehabilitation support for knee and wrist, and Dynacomp for cold compression therapy. Further, it develops Zynex Fluid Monitoring System (CM-1500); Zynex Wireless Fluid Monitoring System (CM-1600), a noninvasive monitoring device designed to measure relative changes in fluid volume in adult patients; NiCO CO-Oximeter, a laser photoplethysmographic patient monitoring device; and HemeOx tHb Oximeter, a laser-based total hemoglobin pulse oximeter. The company provides its products for use in pain management and control; stroke and spinal cord injury rehabilitation; and fluid monitoring and pulse oximetry monitoring. It sells its products through direct sales force primarily in the United States. Zynex, Inc. was founded in 1996 and is headquartered in Englewood, Colorado.
| Name | Title | Year Born |
|---|---|---|
| Mr. Thomas Sandgaard | Founder, Pres, CEO & Chairman | 1959 |
| Mr. Daniel J. Moorhead | Chief Financial Officer | 1972 |
| Ms. Anna Lucsok | Chief Operating Officer | 1986 |
| Ms. Chelle Van Burkleo | VP of Sales | NA |
| Mr. Steve Fox | VP Of Sales | NA |
| Mr. Dave Anttila | Director of HR | NA |
| Mr. Neil Friery | Pres & COO of Zynex Monitoring Solutions, Inc. | NA |
| Mr. Joachim Sandgaard | Information Systems Mang. | NA |
| Mr. Donald Gregg | VP of Sales and Operations - Monitoring Solutions Division | NA |
| Mr. Thomas Sandgaard | Founder, President, CEO & Chairman | 1959 |
Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.